肝癌中血管生成、VEGF及其受體水平與預(yù)后關(guān)系的臨床研究.pdf

1、青島大學碩士學位論文肝癌中血管生成、VEGF及其受體水平與預(yù)后關(guān)系的臨床研究姓名：于麗申請學位級別：碩士專業(yè)：臨床腫瘤學指導(dǎo)教師：梁軍沈方臻2003.5.1壁擅主魚重生盛!!l塑叢墓鐾簽盔壬量塑卮苤丕盥蝤壓嬰囂AssociationofandAngiogenesis，VasouIarEndotheIiumGrowthFactorandItsReceptors’ExpressionwithOutcomeinPrimaryHepatoceI

2、IuIarCarcinoma[Abstract]0bjective：Todeterminetheabsoluteandrelativevalueof，microvesseldensity(MVD)，vascularendotheliumgrowthfactor(VEGF)poteinanditsreceptors(VEGFR：Fit—I、Flk—i、Flt一4)proteinexpressioninprimarytumorandpreo

3、perativeserumVEGFinpredictinsrecurrenceofprimaryhepatocellularcarcinoma(PHCC)PatientsandMethods：Wemonitored60patientswithPHCCforamedianof305monthsIntratumalMVDWaSmeasuredaftermitrovesselswereimmunostainedusinganti—CD34an

4、tibodyVEGFproteinandVEGFRproteinsexpressionwerealsodeterminedimmunohistochemicallYAlso，WedetectedpreoperativeserumVEGFof30patients(fromthe60patients)usingELISA(Enzyme一1inkedin_】fnunoadsordentassay)Resultswereanalyzedbytt

5、est，chi—Squaretest，BivarlatecorrelationanalYsis。univariateandmultivariatestatisticalanalysisResuIts：MVD，VEGF，Plt一1，F(xiàn)lk1andFlt一4expressionandserumVEGFwereallpositivelycorrelatedwithtumordiameter，staging，differentiationand

6、cancerembolus(PO05)MVDVEGF，F(xiàn)it—landFlk一1expressionandserumVEGFwerepositivelYcorrelatedwithrecurrence(P005；0003，00i3，0031，0026respectivelv)UnivatiateanalysiSbyKaplan—MierersurvivalanalysisshowedthatMVD，VEGF，F(xiàn)1t—l，F(xiàn)lk一1and

7、F1t一4expressionandserumVEGFwereallsignificantlYpredictivtofDFS(diseasefreesurvival)(PO05：00045，00287，00021，0093，00472，0020I，respectively)MultivariateanalysisshowedthatMVD。VEGF，F(xiàn)1t—landF1k一1expressionandserumVEGFweresigni

8、ficantandindependentprognosticfactorsforDFS(PO05：0009，0017，0025，0042，00i3respectively)ConcIusion：MVD，VEGF，F(xiàn)it一1andFlk—lexpressionandserumVEGFarea11independentprognosticindicatorsforrecurrenceCombinationofallthesixindicat

9、orswouldbemoreusefulinpredictingprognosisOwingtoitsconvenience，serumVEGFmaybethemostprospectivepredictorforhigh—riskrecurrenceA11theseindictorsareusefulinselectionofhigh—riskrecurrenceofhepatocellularcarcinomapatientswho